- Comm HLA gene typing detection series (SSP) - Accu HLA gene typing detection series (qPCR) - Gold HLA gene typing detection series（SBT） - Next HLA gene typing detection series（NGS）
Now Location：Home--Product Center--Drug metabolism gene testing series [Product Name]
Common name: Cytochrome P450 3A5 Genotyping Detection Reagent Disk (Fluorescence PCR Method)
[Intended use]
This reagent is used for typing and qualitative detection of cytochrome P450 3A5 gene subtypes, including CYP3A5 * 1 subtype and CYP3A53 subtype.
Cytochrome P450 (yochrome P450) CYP is an important drug metabolism enzyme in the human body, and CYP3A is an enzyme in the CYP superfamily that is highly expressed in the liver and intestines. CYP3A5 is an important subtype of this enzyme. It is the main metabolic enzyme of the immunosuppressive agent tacrolimus (FK506) in the human body The expression and activity of CYP3AS exhibit highly variable polymorphism, with significant individual and racial variability. Differences in enzyme activity are the main reason for pharmacokinetic differences. The CYP3A5 gene has multiple single nucleotide polymorphism (SNP) sites, and mutations at the 6989 (ANG) site can cause CYP3A5 to translate into non functional proteins, affecting the metabolism of tacrolimus in vivo. Research has shown that carriers of the CYP3AS * 1 allele have higher levels of CYP3AS expression and stronger enzymatic activity. Resulting in a faster metabolic rate of tacrolimus in the body. Low bioavailability. The blood concentration of tacrolimus in this group of people is often low, which can easily lead to insufficient immune suppression and rejection reactions. From this, it can be seen that genotyping analysis of CYP3AS helps to clinically determine the immunosuppressive regimen of patients and select the appropriate dosage.
[Principle of Inspection]
This reagent disk uses real-time fluorescence PCR combined with Tapman probe technology for qualitative typing detection of CYP3A5 gene. Based on the CYP3AS gene sequence published in the GENBANK database, specific primers were designed using the amplification inhibition mutation system (ARMS) analysis method. The specific probes were labeled with FAM, and two tube reactions were performed for each detection to detect the CYP3AS subtype. At the same time, a pair of internal standard primers and probes were added to the tubes, labeled with HEX, to monitor false negative results caused by instrument malfunctions, reagent factors, polymerase activity, or inhibitors in the sample.
